E
RedHill Biopharma Ltd. RDHL
$1.95 -$0.31-13.72%
Recommendation
Sell
Prev Close
$1.95
Volume
41,826
Avg Vol (90D)
68,216
Market Cap
$2.50M
Dividend & Yield
--
52-Week Range
$1.86 - $20.28
P/E (TTM)
0.00
EPS (TTM)
-$719,968.00
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
RedHill Biopharma to submit UK MAA for Talicia
3/18/2025 - The Fly
RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation
3/18/2025 - PR Newswire
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on ...
3/12/2025 - GuruFocus
RedHill Biopharma announces plans to advance program for Crohn's disease
3/12/2025 - The Fly
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
3/12/2025 - PR Newswire
RedHill Biopharma provides business update on RHB-102, 2025 catalysts
2/27/2025 - The Fly
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
2/27/2025 - PR Newswire
RedHill Biopharma licenses RHB-102 for global commercialization to Hyloris
2/25/2025 - The Fly
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
2/25/2025 - PR Newswire
RedHill Biopharma begins Phase 2 study of prostate cancer combination
2/4/2025 - The Fly
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
2/4/2025 - PR Newswire
RedHill Biopharma's Talicia now covered by Humana's Part D Plan
1/21/2025 - TipRanks Financial Blog
RedHill Biopharma's Talicia now covered by Humana's Part D Plan
1/21/2025 - The Fly
RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
1/21/2025 - PR Newswire
RedHill Biopharma's opaganib shows radioprotective activity in study
12/10/2024 - The Fly
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
12/10/2024 - PR Newswire
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
12/2/2024 - GuruFocus
RedHill Biopharma Wins $8 Million Court Judgment
12/2/2024 - TipRanks Financial Blog
RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court
12/2/2024 - The Fly
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
12/2/2024 - PR Newswire
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
11/4/2024 - PR Newswire
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
10/28/2024 - PR Newswire
RedHill Biopharma signs research pact with Duke University School of Medicine
10/22/2024 - TipRanks Financial Blog
RedHill Biopharma signs research pact with Duke University School of Medicine
10/22/2024 - The Fly
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
10/22/2024 - PR Newswire
Income Statement
Total Revenue (TTM)
$3.71M
EBITDA (TTM)
-$19.51M
EBIT (TTM)
-$20.49M
Net Income (TTM)
-$30.17M
Balance Sheet
Total Assets (Q)
$22.02M
Total Debt (Q)
$558.00K
Total Liabilities (Q)
$21.96M
Book Value Per Share (Q)
$519.00
Cash Flow
Cash from Operations (TTM)
-$24.23M
Cash from Investing (TTM)
$10.00K
Cash from Financing (TTM)
$24.53M
Net Change in Cash (TTM)
$281.00K
Filings
Filing Date
Thursday, August 29, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Apr 7 and 11 (est)
Price History
Loading...
Beta
1.18
7-Day Total Return
-29.09%
30-Day Total Return
-59.54%
60-Day Total Return
-68.85%
90-Day Total Return
-71.24%
Year to Date Total Return
-69.53%
1-Year Total Return
-85.26%
2-Year Total Return
-97.60%
3-Year Total Return
-99.92%
5-Year Total Return
-99.97%
52-week Low
Apr 04, 2025 - $1.86
52-week High
Aug 01, 2024 - $20.28
Valuation
Market Cap
$2.50M - Nano Cap
Enterprise Value
-$4.22M
Price/Sales (TTM)
0.00
Price/Book (Q)
0.00
Dividends and Shares
Shares Outstanding
100.00
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.redhillbio.com
Phone Number
972 3 541 3131
Address
21 Ha’arba’a Street
Tel Aviv, 6473921
Country
Israel
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of... more
NASDAQ 04/04/2025 3:59PM Eastern Quotes delayed
Weiss Ratings